MeCP2 reinforces STAT3 signaling and the generation of effector CD4 + T cells by promoting miR-124-mediated suppression of SOCS5

Science Signaling

Volumn 7, Issue 316, 2014, Pages

  Jiang, Shan ^a   Li, Chaoran ^a   McRae, Gabrielle ^a   Lykken, Erik ^a   Sevilla, Jose ^a   Liu, Si Qi ^a   Wan, Ying ^b   Li, Qi Jing ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CILIARY NEUROTROPHIC FACTOR; GAMMA INTERFERON; HISTONE H3; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 6; METHYL CPG BINDING PROTEIN 2; MICRORNA 124; NEUROTROPHIC FACTOR; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 5; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE RESISTANCE; HISTONE ACETYLATION; IMMUNE RESPONSE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CHROMATIN IMMUNOPRECIPITATION; CYTOKINES; DNA METHYLATION; GENE EXPRESSION REGULATION; HISTOLOGICAL TECHNIQUES; LUCIFERASES; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, KNOCKOUT; MICRORNAS; ORGANIC CHEMICALS; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84896103307     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004824     Document Type: Article

References (62)

1. J. D. Lewis, R. R. Meehan, W. J. Henzel, I. Maurer-Fogy, P. Jeppesen, F. Klein, A. Bird, Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69, 905-914 (1992).
2. R. R. Meehan, J. D. Lewis, A. P. Bird, Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20, 5085-5092 (1992).
3. X. Nan, F. J. Campoy, A. Bird, MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471-481 (1997).
4. X. Nan, H. H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N. Eisenman, A. Bird, Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998).
5. J. Guy, H. Cheval, J. Selfridge, A. Bird, The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27, 631-652 (2011).
6. K. C. Hite, V. H. Adams, J. C. Hansen, Recent advances in MeCP2 structure and function. Biochem. Cell Biol. 87, 219-227 (2009).
7. J. I. Young, E. P. Hong, J. C. Castle, J. Crespo-Barreto, A. B. Bowman, M. F. Rose, D. Kang, R. Richman, J. M. Johnson, S. Berget, H. Y. Zoghbi, Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U.S.A. 102, 17551-17558 (2005).
8. P. T. Georgel, R. A. Horowitz-Scherer, N. Adkins, C. L.Woodcock, P. A. Wade, J. C. Hansen, Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 278, 32181-32188 (2003).
9. S. Horike, S. Cai, M. Miyano, J. F. Cheng, T. Kohwi-Shigematsu, Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 37, 31-40 (2005).
10. M. Chahrour, S. Y. Jung, C. Shaw, X. Zhou, S. T. Wong, J. Qin, H. Y. Zoghbi, MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008).
11. D. H. Yasui, S. Peddada, M. C. Bieda, R. O. Vallero, A. Hogart, R. P. Nagarajan, K. N. Thatcher, P. J. Farnham, J. M. Lasalle, Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. U.S.A. 104, 19416-19421 (2007).
12. A. Rett, [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien. Med. Wochenschr. 116, 723-726 (1966).
13. R. E. Amir, I. B. Van den Veyver, M. Wan, C. Q. Tran, U. Francke, H. Y. Zoghbi, Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
14. C. L. Laurvick, N. de Klerk, C. Bower, J. Christodoulou, D. Ravine, C. Ellaway, S. Williamson, H. Leonard, Rett syndrome in Australia: A review of the epidemiology. J. Pediatr. 148, 347-352 (2006).
15. B. Hagberg, Rett's syndrome: Prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr. Scand. 74, 405-408 (1985).
16. J. L. Neul, P. Fang, J. Barrish, J. Lane, E. B. Caeg, E. O. Smith, H. Zoghbi, A. Percy, D. G. Glaze, Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome. Neurology 70, 1313-1321 (2008).
17. R. Z. Chen, S. Akbarian, M. Tudor, R. Jaenisch, Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327-331 (2001).
18. D. T. Lioy, S. K. Garg, C. E. Monaghan, J. Raber, K. D. Foust, B. K. Kaspar, P. G. Hirrlinger, F. Kirchhoff, J. M. Bissonnette, N. Ballas, G. Mandel, A role for glia in the progression of Rett's syndrome. Nature 475, 497-500 (2011).
19. D. D. Armstrong, Neuropathology of Rett syndrome. J. Child Neurol. 20, 747-753 (2005).
20. K. Jellinger, F. Seitelberger, Neuropathology of Rett syndrome. Am. J. Med. Genet. Suppl. 1, 259-288 (1986).
21. A. H. Sawalha, R. Webb, S. Han, J. A. Kelly, K. M. Kaufman, R. P. Kimberly, M. E. Alarcón-Riquelme, J. A. James, T. J. Vyse, G. S. Gilkeson, C. B. Choi, R. H. Scofield, S. C. Bae, S. K. Nath, J. B. Harley, Common variants within MECP2 confer risk of systemic lupus erythematosus. PLOS One 3, e1727 (2008).
22. R.Webb, J. D.Wren, M. Jeffries, J. A. Kelly, K. M. Kaufman, Y. Tang, M. B. Frank, J. Merrill, R. P. Kimberly, J. C. Edberg, R. Ramsey-Goldman, M. Petri, J. D. Reveille, G. S. Alarcón, L. M. Vilá, M. E. Alarcón-Riquelme, J. A. James, T. J. Vyse, K. L. Moser, P. M. Gaffney, G. S. Gilkeson, J. B. Harley, A. H. Sawalha, Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum. 60, 1076-1084 (2009).
23. B. L. Cobb, Y. Fei, R. Jonsson, A. I. Bolstad, J. G. Brun, M. Rischmueller, S. E. Lester, T. Witte, G. Illei, M. Brennan, S. Bowman, K. L. Moser, J. B. Harley, A. H. Sawalha, Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome. Ann. Rheum. Dis. 69, 1731-1732 (2010).
24. G. Lal, N. Zhang, W. van der Touw, Y. Ding, W. Ju, E. P. Bottinger, S. P. Reid, D. E. Levy, J. S. Bromberg, Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182, 259-273 (2009).
25. R. C. Samaco, J. D. Fryer, J. Ren, S. Fyffe, H. T. Chao, Y. Sun, J. J. Greer, H. Y. Zoghbi, J. L. Neul, A partial loss of function allele of Methyl-CpG-Binding Protein 2 predicts a human neurodevelopmental syndrome. Hum. Mol. Genet. 17, 1718-1727 (2008).
26. B. Kerr, M. Alvarez-Saavedra, M. A. Sáez, A. Saona, J. I. Young, Defective body-weight regulation, motor control and abnormal social interactions in Mecp2 hypomorphic mice. Hum. Mol. Genet. 17, 1707-1717 (2008).
27. D. V. Ostanin, J. Bao, I. Koboziev, L. Gray, S. A. Robinson-Jackson, M. Kosloski-Davidson, V. H. Price, M. B. Grisham, T cell transfer model of chronic colitis: Concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G135-G146 (2009).
28. M. Saleh, C. O. Elson, Experimental inflammatory bowel disease: Insights into the host-microbiota dialog. Immunity 34, 293-302 (2011).
29. J. Zhu, H. Yamane, W. E. Paul, Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28, 445-489 (2010).
30. + helper T cells involved in primary and secondary responses to infection. Proc. Natl. Acad. Sci. U.S.A. 109, 9511-9516 (2012).
31. M. Sospedra, R. Martin, Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747 (2005).
32. D. Luger, P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N.M. Sgambellone, C. C. Chan, R. R. Caspi, Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799-810 (2008).
33. C. B. Wilson, E. Rowell, M. Sekimata, Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9, 91-105 (2009).
34. X. O. Yang, A. D. Panopoulos, R. Nurieva, S. H. Chang, D. Wang, S. S. Watowich, C. Dong, STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358-9363 (2007).
35. H17-dependent autoimmunity. J. Immunol. 179, 4313-4317 (2007).
36. T. Korn, E. Bettelli, M. Oukka, V. K. Kuchroo, IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517 (2009).
37. S. Dziennis, N. J. Alkayed, Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. Rev. Neurosci. 19, 341-361 (2008).
38. T. Taga, Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J. Neurochem. 67, 1-10 (1996).
39. J. J. O'Shea, P. J. Murray, Cytokine signaling modules in inflammatory responses. Immunity 28, 477-487 (2008).
40. Y. Seki, K. Hayashi, A. Matsumoto, N. Seki, J. Tsukada, J. Ransom, T. Naka, T. Kishimoto, A. Yoshimura, M. Kubo, Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc. Natl. Acad. Sci. U.S.A. 99, 13003-13008 (2002).
41. C. Brender, R. Columbus, D. Metcalf, E. Handman, R. Starr, N. Huntington, D. Tarlinton, N. Ødum, S. E. Nicholson, N. A. Nicola, D. J. Hilton, W. S. Alexander, SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. Mol. Cell. Biol. 24, 6094-6103 (2004).
42. S. E. Nicholson, T. A. Willson, A. Farley, R. Starr, J. G. Zhang, M. Baca, W. S. Alexander, D. Metcalf, D. J. Hilton, N. A. Nicola, Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18, 375-385 (1999).
43. M. R. Fabian, N. Sonenberg, W. Filipowicz, Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351-379 (2010).
44. H. Guo, N. T. Ingolia, J. S. Weissman, D. P. Bartel, Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
45. M. Lagos-Quintana, R. Rauhut, A. Yalcin, J. Meyer, W. Lendeckel, T. Tuschl, Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 735-739 (2002).
46. R. Sanuki, A. Onishi, C. Koike, R. Muramatsu, S. Watanabe, Y. Muranishi, S. Irie, S. Uneo, T. Koyasu, R. Matsui, Y. Chérasse, Y. Urade, D. Watanabe, M. Kondo, T. Yamashita, T. Furukawa, miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat. Neurosci. 14, 1125-1134 (2011).
47. C. Ledderose, P. Möhnle, E. Limbeck, S. Schütz, F. Weis, J. Rink, J. Briegel, S. Kreth, Corticosteroid resistance in sepsis is influenced by microRNA-124 -induced down-regulation of glucocorticoid receptor-a. Crit. Care Med. 40, 2745- 2753 (2012).
48. S. Jiang, C. Li, V. Olive, E. Lykken, F. Feng, J. Sevilla, Y. Wan, L. He, Q. J. Li, Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118, 5487-5497 (2011).
49. S. Obad, C. O. dos Santos, A. Petri, M. Heidenblad, O. Broom, C. Ruse, C. Fu, M. Lindow, J. Stenvang, E. M. Straarup, H. F. Hansen, T. Koch, D. Pappin, G. J. Hannon, S. Kauppinen, Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371-378 (2011).
50. A. F. Freeman, S. M. Holland, Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr. Res. 65, 32R-37R (2009).
51. A. K. Percy, H. S. Lee, J. L. Neul, J. B. Lane, S. A. Skinner, S. P. Geerts, F. Annese, J. Graham, L. McNair, K. J. Motil, J. O. Barrish, D. G. Glaze, Profiling scoliosis in Rett syndrome. Pediatr. Res. 67, 435-439 (2010).
52. H. Zhou, A. B. Newnum, J. R. Martin, P. Li, M. T. Nelson, A. Moh, X. Y. Fu, H. Yokota, J. Li, Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone 49, 404-411 (2011).
53. M. Chahrour, H. Y. Zoghbi, The story of Rett syndrome: From clinic to neurobiology. Neuron 56, 422-437 (2007).
54. M. J. Friez, J. R. Jones, K. Clarkson, H. Lubs, D. Abuelo, J. A. Bier, S. Pai, R. Simensen, C. Williams, P. F. Giampietro, C. E. Schwartz, R. E. Stevenson, Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics 118, e1687-e1695 (2006).
55. T. Yang, M. B. Ramocki, J. L. Neul, W. Lu, L. Roberts, J. Knight, C. S.Ward, H. Y. Zoghbi, F. Kheradmand, D. B. Corry, Overexpression of methyl-CpG binding protein 2 impairs TH1 responses. Sci. Transl. Med. 4, 163ra158 (2012).
56. H. Kimura, K. Shiota, Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J. Biol. Chem. 278, 4806-4812 (2003).
57. M. Tudor, S. Akbarian, R. Z. Chen, R. Jaenisch, Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. U.S.A. 99, 15536-15541 (2002).
58. E. Ballestar, S. Ropero, M. Alaminos, J. Armstrong, F. Setien, R. Agrelo, M. F. Fraga, M. Herranz, S. Avila, M. Pineda, E. Monros, M. Esteller, The impact of MECP2 mutations in the expression patterns of Rett syndrome patients. Hum. Genet. 116, 91-104 (2005).
59. J. Traynor, P. Agarwal, L. Lazzeroni, U. Francke, Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med. Genet. 3, 12 (2002).
60. J. H. Gibson, B. Slobedman, K. N. Harikrishnan, S. L. Williamson, D. Minchenko, A. El-Osta, J. L. Stern, J. Christodoulou, Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci. 11, 53 (2010).
61. S. Ben-Shachar, M. Chahrour, C. Thaller, C. A. Shaw, H. Y. Zoghbi, Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 18, 2431-2442 (2009).
62. F. Xiao, Z. Zuo, G. Cai, S. Kang, X. Gao, T. Li, miRecords: An integrated resource for microRNA-target interactions. Nucleic Acids Res. 37, D105-D110 (2009).